ACOR - Acorda Therapeutics gets Nasdaq delisting notice plans to appeal decision
- Acorda Therapeutics ( NASDAQ: ACOR ) said Tuesday it received a Nasdaq notice indicating that its shares will be delisted unless the firm timely requests a hearing before the Nasdaq Hearings Panel.
- Nasdaq's decision is based on ACOR's non-compliance with the filing requirement for continued listing with the minimum price of $1.00.
- Letter from Nasdaq notified that, unless ACOR requests a timely hearing, its securities would be subject to delisting.
- ACOR intends to request a hearing before a Nasdaq panel at which it will request a further extension of time.
For further details see:
Acorda Therapeutics gets Nasdaq delisting notice, plans to appeal decision